Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease in which the body’s immune system attacks the optic nerves and spinal cord, and sometimes the brainstem. It affects roughly 7 per 100,000 people in the United States and is often mistaken for multiple sclerosis, though it has a distinct cause, a specific blood marker, and its own set of approved treatments.
How NMOSD Differs From Multiple Sclerosis
For decades, NMOSD was considered a variant of multiple sclerosis (MS). That changed with the discovery of a specific antibody called AQP4-IgG, which is found in about 76% of NMOSD patients and virtually none with MS. This antibody targets a water-channel protein that sits on the surface of certain brain cells, and its presence in a blood test is now the single most important factor in distinguishing the two conditions.
The differences go beyond lab results. NMOSD tends to strike later in life, affects women at a higher rate, and causes more severe attacks that concentrate in the optic nerves and spinal cord. MS lesions, by contrast, are spread more broadly across the brain. At initial presentation, NMOSD patients are more likely to experience sensory disturbances (77% vs. 55% in MS), motor dysfunction (63% vs. 41%), visual impairment (45% vs. 24%), and bladder or bowel problems (47% vs. 10%). People with NMOSD also have a notably higher rate of coexisting autoimmune conditions, with about 20% having another autoimmune disease compared to roughly 3% of MS patients.
What Happens Inside the Body
The damage in NMOSD starts with the AQP4-IgG antibody. This antibody locks onto aquaporin-4, a water-channel protein concentrated on star-shaped brain cells called astrocytes, particularly where those cells wrap around blood vessels. Once the antibody binds, it triggers the body’s complement system, a branch of the immune response that punches holes in cell membranes. The astrocytes are destroyed first, and the damage cascades outward.
The antibody also disrupts how astrocytes regulate glutamate, a chemical that nerve cells use to communicate. Normally, astrocytes mop up excess glutamate to keep levels safe. When the antibody binding causes astrocytes to pull the water-channel protein inside, a glutamate transporter disappears along with it. At the same time, the enzyme that breaks down glutamate becomes less active. The result is a toxic buildup that can injure nerve fibers and the protective myelin coating around them. On top of that, damaged astrocytes release inflammatory signals that recruit additional immune cells, compounding the destruction.
Symptoms and Core Clinical Features
NMOSD produces attacks, called relapses, that can affect several distinct areas of the central nervous system. The 2015 international diagnostic criteria identify six core presentations, but three dominate the clinical picture.
Optic neuritis causes sudden vision loss or pain with eye movement, typically in one eye at a time. It can be severe, and in one study, three out of four NMOSD patients with optic neuritis still had significant visual impairment a year later.
Transverse myelitis involves inflammation of a long stretch of the spinal cord, often spanning three or more vertebral segments. It can cause numbness, weakness, or paralysis in the limbs, along with loss of bladder or bowel control. Isolated myelitis is more common in NMOSD than in the related condition MOGAD.
Area postrema syndrome is one of the most distinctive features of NMOSD. The area postrema is a small structure at the base of the brainstem that controls the vomiting reflex and lacks a normal blood-brain barrier, making it especially vulnerable to antibody attack. When inflamed, it causes bouts of uncontrollable nausea, vomiting, or hiccups that can last days or weeks. In about 43% of these episodes, all three symptoms occur together. Hiccups were described as nonstop for more than 24 hours in 30% of attacks. These symptoms are often initially attributed to a gastrointestinal problem, delaying the correct diagnosis.
Less common presentations include other brainstem symptoms (such as double vision or facial numbness), episodes involving brain regions that regulate hormones and sleep, and seizures or confusion from cerebral inflammation.
Who Gets NMOSD
NMOSD has a striking demographic profile. Women account for nearly 78% of cases, with an overall female-to-male ratio of 3.5 to 1. The disease is most common between ages 35 and 65, with prevalence in that window exceeding 9.5 per 100,000.
Race and ethnicity matter significantly. In the U.S., Black Americans have the highest prevalence at about 13 per 100,000, followed by Asian Americans at 9.4 per 100,000 and white Americans at 5.6 per 100,000. The disparity is sharpest among women: Black women aged 35 to 64 carry a prevalence above 25 per 100,000, roughly five times the rate seen in white males of any age. These patterns suggest that both genetic susceptibility and immune system factors vary across populations.
How NMOSD Is Diagnosed
Diagnosis follows the 2015 international consensus criteria. If the AQP4-IgG antibody test is positive, only one core clinical event is required for diagnosis. If the antibody is negative or testing is unavailable, the bar is higher: at least two different core clinical events affecting different parts of the nervous system, plus supporting findings on MRI.
For antibody-negative patients, at least one of those events must be optic neuritis, transverse myelitis with a long spinal cord lesion on MRI, or area postrema syndrome with a corresponding brainstem lesion. This tiered approach reflects the reality that about one in four NMOSD patients does not test positive for AQP4-IgG, and diagnosis in that group requires more clinical evidence.
A related condition, MOG antibody-associated disease (MOGAD), can look similar to NMOSD but involves a different antibody targeting myelin. MOGAD tends to appear at a younger age (average 26 vs. 35 for NMOSD), affects more men, and generally carries a better prognosis. Patients with MOGAD recover faster, respond better to standard immune treatments, and accumulate less disability over time. Distinguishing the two matters because their long-term management differs.
Treating Acute Attacks
When a relapse hits, the standard first step is high-dose intravenous steroids for five days. Steroids alone, however, produce only moderate recovery. Adding plasma exchange, a procedure that filters harmful antibodies from the blood, significantly improves outcomes. In one study, 51% of patients who received both steroids and plasma exchange returned to their pre-attack level of function by hospital discharge, compared to just 17% of those who received steroids alone. At follow-up, 65% of the combination group had recovered to baseline versus 35% of the steroid-only group.
The median improvement in disability scores was 1.25 points with the combination approach, versus 0.5 points with steroids alone. Because of this gap, plasma exchange is typically started in the second week if steroids haven’t produced adequate improvement.
Preventing Relapses
Relapse prevention is the cornerstone of long-term NMOSD care, because each attack risks permanent damage. Four monoclonal antibody therapies are now FDA-approved for AQP4-IgG-positive NMOSD, each targeting a different step in the inflammatory chain:
- Eculizumab and ravulizumab block a complement protein called C5, preventing the immune system from assembling the molecular complex that destroys astrocytes.
- Inebilizumab depletes B cells, the immune cells responsible for producing the AQP4-IgG antibody, by targeting a surface marker called CD19.
- Satralizumab blocks the receptor for interleukin-6, an inflammatory signaling molecule. This reduces antibody production, dials down a specific type of inflammatory immune cell response, and helps maintain the blood-brain barrier.
All four drugs are highly effective at reducing relapse rates. Rituximab, an older B cell-depleting therapy that targets a different surface marker (CD20), is also widely used off-label and was the most common preventive treatment before the newer approvals.
Recovery and Long-Term Outlook
NMOSD is a relapsing disease, and the damage it causes is cumulative. Across all attacks in one large study, full recovery occurred after only about 25% of episodes. Age plays a major role in outcomes: patients diagnosed before age 50 achieved complete recovery 27% of the time, while those diagnosed later recovered fully in just 16% of attacks. For patients whose disease began after age 75, full recovery dropped to 6%.
The disability that accumulates with each incompletely recovered attack is the primary driver of long-term impairment. Younger patients tend to bounce back more, but even they face residual deficits. Spinal cord attacks carry especially poor recovery rates regardless of age, and visual loss from optic neuritis often persists. Annualized attack rates average roughly 0.5 per year, meaning most patients experience a relapse every one to two years without preventive treatment.
Managing Chronic Pain and Spasms
Pain is one of the most common and undertreated aspects of NMOSD. Nerve damage from spinal cord attacks often leaves behind chronic neuropathic pain, burning sensations, or painful tonic spasms, which are sudden, involuntary muscle contractions.
Anti-seizure medications are the most effective first-line option for both neuropathic pain and spasms. Gabapentin is typically the starting point, with doses gradually increased over several weeks. Carbamazepine, another anti-seizure drug, is particularly useful for both pain types and can be combined with gabapentin when one alone isn’t enough. If that combination falls short, certain antidepressants are added next, not for mood but because they alter pain signaling. Amitriptyline, taken at bedtime, is especially effective but can cause drowsiness. Duloxetine is an alternative for those who can’t tolerate the sedation.
For persistent spasticity rather than intermittent spasms, muscle relaxants like baclofen can reduce stiffness, though they may also increase a sense of weakness, particularly during walking. Strong analgesics are reserved as a last resort while other approaches are explored through trial and error.